<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464019</url>
  </required_header>
  <id_info>
    <org_study_id>MSP-2017-1138</org_study_id>
    <nct_id>NCT03464019</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]</brief_title>
  <official_title>Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milestone Pharmaceuticals Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milestone Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the efficacy and safety of etripamil NS self-administered by patients who experience&#xD;
      an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting.&#xD;
&#xD;
      Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of&#xD;
      150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301&#xD;
      study after the completion of Part 1.&#xD;
&#xD;
      The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not&#xD;
      dosed with the double-blind study drug, or had not discontinued the study before the&#xD;
      adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients&#xD;
      enrolled into the study following the completion of Part 1. Enrollment will continue until&#xD;
      and for approximately 6 months after the date of the adjudication of the 180th positively&#xD;
      adjudicated PSVT episode.&#xD;
&#xD;
      The study will include the following visits: A Screening Visit, A Test Dose Randomization&#xD;
      Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period&#xD;
      Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NODE-301 is a two-part, multi-center, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the efficacy and safety of etripamil NS self-administered by patients who experience&#xD;
      an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Each episode&#xD;
      will be documented by an ambulatory Cardiac Monitoring System (CMS) that will be placed on&#xD;
      the chest by the patient or caregiver when symptoms begin and will record at least 5 hours of&#xD;
      continuous electrocardiogram (ECG).&#xD;
&#xD;
      This is an event-driven study. The study is comprised of 2 parts: Part 1 and Part 2.&#xD;
&#xD;
      Part 1 comprised the conduct of NODE-301 up to the date of the adjudication of the 150th&#xD;
      positively adjudicated PSVT episode (January 15th, 2020). Part 1 had the same general study&#xD;
      design as Part 2 of the study, with the key differences being that Part 2 includes a repeat&#xD;
      dosing option during the randomized treatment phase, as well as during an added open-label&#xD;
      treatment phase.&#xD;
&#xD;
      Part 2 (the RAPID Study) describes the conduct of NODE-301 following the completion of Part&#xD;
      1. RAPID will enroll patients enrolled during Part 1 who had not dosed with the double-blind&#xD;
      study drug, or had not discontinued the study before the adjudication of the 150th positively&#xD;
      adjudicated PSVT episode in Part 1, and patients enrolled into the study following the&#xD;
      completion of Part 1.&#xD;
&#xD;
      Before randomization in the RAPID study, all patients will receive a test dose of an&#xD;
      etripamil NS dosing regimen (an initial dose of etripamil NS 70 mg followed by a second dose&#xD;
      of etripamil NS 70 mg not earlier than 10 minutes and not later than 15 minutes after the&#xD;
      first dose) to evaluate tolerability and to train patients on the study procedures.&#xD;
&#xD;
      The RAPID Study includes a Screening Visit, a Test Dose Randomization Visit, Monthly&#xD;
      Follow-up Visits, a Randomized Treatment Period, a Randomized Treatment Period Follow-Up&#xD;
      Visit, an Open-Label Treatment Period, and a Final Study Visit.&#xD;
&#xD;
      Study comprised of 4 arms:&#xD;
&#xD;
        -  2 arms consisting of patients enrolled during Part 1 randomized 2:1 to a single dose of&#xD;
           study drug (etripamil NS 70 mg or placebo) to treat a perceived episode of PSVT&#xD;
&#xD;
        -  2 arms consisting of newly enrolled patients who pass a test dose regimen of etripamil&#xD;
           NS 70 mg, randomized 1:1 to a dosing regimen of etripamil or placebo that allows&#xD;
           patients to self-administer a second dose (not earlier than 10 minutes and not later&#xD;
           than 15 minutes after the first dose) of study drug if symptoms are still present at 10&#xD;
           minutes, to treat a perceived PSVT episode.&#xD;
&#xD;
      Safety will be monitored during the treatment periods.&#xD;
&#xD;
      To ensure the safety of trial participants in RAPID, new processes or modification of listed&#xD;
      processes may be put in place to reduce the risks associated with the COVID-19 pandemic.&#xD;
      These potential changes include, but are not limited to, the use of tele-medicine to conduct&#xD;
      study visit procedures, conduct of study procedures outside of the clinical site (i.e., at a&#xD;
      patient's home) by site personnel or by trained but non-study personnel, and the distribution&#xD;
      of investigational products by alternative secure delivery methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study comprised of 4 arms:&#xD;
2 arms consisting of patients enrolled during Part 1 randomized 2:1 to a single dose of study drug (etripamil NS 70 mg or placebo) to treat a perceived episode of PSVT.&#xD;
2 arms consisting of newly enrolled patients who pass a test dose regimen of etripamil NS 70 mg, randomized 1:1 to a dosing regimen of etripamil or placebo that allows patients to self-administer a second dose (not earlier than 10 minutes and not later than 15 minutes after the first dose) of study drug if symptoms are still present at 10 minutes, to treat a perceived PSVT episode.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>RAPID study (NODE-301 Part 2) includes an open-label treatment phase following the randomized treatment phase of the study.&#xD;
The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit. Patients who report no tolerability issues (i.e. adverse events) related to the study drug after having finished the Randomized Treatment Period, will be entered into the Open-Label Treatment Period while the patients who have not tolerated the double-blind study drug will pass to the Final Study Visit.&#xD;
Patients comprising the single dose arms will not be entered into the open-label treatment phase of the RAPID study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The time to conversion of an episode of PSVT to sinus rhythm (SR) after study drug administration.</measure>
    <time_frame>Within 30 minutes of start of study drug dosing.</time_frame>
    <description>The primary efficacy endpoint is defined as an adjudicated termination of a positively adjudicated episode of PSVT (AV nodal reentrant tachycardia or AV reentrant tachycardia determination if possible) and conversion to sinus rhythm (SR) for at least 30 seconds within 30 minutes of start of study drug dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relief of specific symptoms (i.e., heart palpitations, rapid pulse feeling, chest pain, anxiety, shortness of breath, dizziness, and fainting) potentially associated with an episode of PSVT.</measure>
    <time_frame>5 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of Treatment Satisfaction Questionnaire for Medication (TSQM).</measure>
    <time_frame>5 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of positively adjudicated episodes of PSVT terminated by a vagal maneuver (VM).</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of patients requiring additional medical intervention to terminate an episode of PSVT.</measure>
    <time_frame>5 hours after administration of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The repeat of key efficacy endpoints in various subgroups of interest (e.g., concomitant medications).</measure>
    <time_frame>5 hours after administration of study drug</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Paroxysmal Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Etripamil 70 mg Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Self- administration of a single dose of 70 mg of etripamil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Self- administration of a single dose of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etripamil 70 mg with Optional Second Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen that permits a second dose of etripamil 70 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Optional Second Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing regimen that permits a second dose of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etripamil</intervention_name>
    <description>Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.</description>
    <arm_group_label>Etripamil 70 mg Single Dose</arm_group_label>
    <arm_group_label>Etripamil 70 mg with Optional Second Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.</description>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_label>Placebo with Optional Second Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet all of the following criteria will be eligible to participate in the&#xD;
        study:&#xD;
&#xD;
          1. Male or female patients at least 18 years of age;&#xD;
&#xD;
          2. Electrographically documented history of PSVT (e.g., electrocardiogram [ECG] obtained&#xD;
             during an episode of PSVT, Holter monitoring, loop recorder, etc). If patient had a&#xD;
             prior ablation for PSVT, patient must have documented ECG evidence of PSVT&#xD;
             post-ablation;&#xD;
&#xD;
          3. History of sustained episodes of PSVT (i.e., typically lasting approximately 20&#xD;
             minutes or longer);&#xD;
&#xD;
          4. Females of childbearing potential must agree to use an approved highly effective form&#xD;
             of contraception from the time of signed informed consent until 30 days after the last&#xD;
             administration of study drug and should have a negative serum pregnancy test result at&#xD;
             the Screening Visit, a negative urine pregnancy test at the Test Dose Randomization&#xD;
             Visit and must use an approved form of contraception between the 2 visits. Approved&#xD;
             forms of contraception include hormonal intrauterine devices, hormonal contraceptives&#xD;
             (oral birth control pills, Depo-Provera®, patch, or other injectables) together with&#xD;
             supplementary double-barrier methods, such as condoms or diaphragms with spermicidal&#xD;
             gel or foam.&#xD;
&#xD;
             The following categories define females who are NOT considered to be of childbearing&#xD;
             potential:&#xD;
&#xD;
               -  Premenopausal females with 1 of the following:&#xD;
&#xD;
                    1. Documented hysterectomy,&#xD;
&#xD;
                    2. Documented bilateral salpingectomy or tubal ligation; or&#xD;
&#xD;
                    3. Documented bilateral oophorectomy, or&#xD;
&#xD;
               -  Premenopausal females who are sexually active with a partner who is surgically&#xD;
                  sterile (i.e.vasectomy);&#xD;
&#xD;
               -  Postmenopausal females, defined as having amenorrhea for at least 12 months&#xD;
                  without an alternative medical cause;&#xD;
&#xD;
          5. Male patients, except those who are surgically sterile, must use an approved highly&#xD;
             effective form of contraception during the 3 days after any study drug administration;&#xD;
             and&#xD;
&#xD;
          6. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria will be excluded from participation in the&#xD;
        study:&#xD;
&#xD;
          1. Systolic blood pressure &lt;90 mmHg after a 5-minute rest in sitting position at the&#xD;
             Screening Visit or before the test dose. In patients treated with a chronic&#xD;
             prophylactic drug for PSVT (e.g., beta-blockers, verapamil, and diltiazem), the drug&#xD;
             may be stopped for at least the equivalent of 5 half-lives and patients may be&#xD;
             rescreened once;&#xD;
&#xD;
          2. History of severe symptoms of hypotension, especially syncope, during episodes of&#xD;
             PSVT;&#xD;
&#xD;
          3. History of atrial arrhythmia that does not involve the AV node as part of the&#xD;
             tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial&#xD;
             tachycardia);&#xD;
&#xD;
          4. History of allergic reaction to verapamil;&#xD;
&#xD;
          5. Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if&#xD;
             these drugs are stopped at least the equivalent of 5 half-lives before the Test Dose&#xD;
             Randomization Visit;&#xD;
&#xD;
          6. Current therapy with amiodarone, or have taken amiodarone within 30 days prior to the&#xD;
             Test Dose Randomization Visit;&#xD;
&#xD;
          7. Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval &lt;100&#xD;
             msec, Wolff-Parkinson-White syndrome) on the ECG performed at the Screening Visit or&#xD;
             before the test dose administration;&#xD;
&#xD;
          8. Evidence of a second- or third-degree AV block on the ECG performed at the Screening&#xD;
             Visit or before the test dose administration;&#xD;
&#xD;
          9. History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes,&#xD;
             ventricular fibrillation, or sustained ventricular tachycardia);&#xD;
&#xD;
         10. Current congestive heart failure defined by the New York Heart Association Class II to&#xD;
             IV;&#xD;
&#xD;
         11. Stroke in the last 6 months;&#xD;
&#xD;
         12. Evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate&#xD;
             aminotransferase &gt;3 × the upper limit of normal (ULN) or total bilirubin &gt;2 × ULN at&#xD;
             the Screening Visit, unless due to Gilbert syndrome;&#xD;
&#xD;
         13. Evidence of renal dysfunction as determined by an estimated glomerular filtration rate&#xD;
             assessed at the Screening Visit as follows:&#xD;
&#xD;
               1. &lt;60 mL/min/1.73 m2 for patients &lt;60 years of age;&#xD;
&#xD;
               2. &lt;40 mL/min/1.73 m2 for patients ≥60 and &lt;70 years of age; or&#xD;
&#xD;
               3. &lt;35 mL/min/1.73 m2 for patients ≥70 years of age;&#xD;
&#xD;
         14. Females who are pregnant or lactating;&#xD;
&#xD;
         15. Evidence or history of any significant physical or psychiatric condition including&#xD;
             drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of&#xD;
             patients, or affect their participation in the study. Additionally, the Investigator&#xD;
             has the ability to exclude a patient if for any reason the Investigator judges the&#xD;
             patient is not a good candidate for the study or will not be able to follow study&#xD;
             procedures;&#xD;
&#xD;
         16. Participation in any investigational drug or device study or the use of any&#xD;
             investigational drug or device within 30 days of the Screening Visit; or&#xD;
&#xD;
         17. Previously enrolled in a clinical trial for etripamil and received study drug during a&#xD;
             perceived episode of PSVT.&#xD;
&#xD;
        Before randomization, in the RAPID study all patients will receive a test dose of etripamil&#xD;
        NS 70 mg to evaluate tolerability and to train patients for the procedures. A failure of&#xD;
        the test dose is considered if patients meet any of the following criteria occurring after&#xD;
        administration of the etripamil NS 70 mg test dose:&#xD;
&#xD;
          1. Any symptoms consistent with clinically severe hypotension such as pre-syncope,&#xD;
             medically significant lightheadedness, syncope, nausea, or vomiting;&#xD;
&#xD;
          2. For patients with a pre-test dose Systolic Blood Pressure above 100 mmHg:&#xD;
&#xD;
               1. Decrease in SBP ≥40 mmHg after test dose; or&#xD;
&#xD;
               2. Post-test dose SBP &lt;80 mmHg;&#xD;
&#xD;
          3. For patients with a pre-test dose SBP between 90 mmHg and 100 mmHg (inclusive):&#xD;
&#xD;
             a) Post-test dose SBP &lt;75 mmHg;&#xD;
&#xD;
          4. Third-degree AV block, Mobitz II second-degree AV block, or Wenckebach with&#xD;
             bradycardia ≤40 bpm;&#xD;
&#xD;
          5. New, significant sinus bradycardia Heart Rate ≤40 bpm or sinus pauses (≤3 seconds), if&#xD;
             considered by the Investigator to put the patient's safety at risk if either were to&#xD;
             occur while not under medical supervision;&#xD;
&#xD;
          6. Any new significant ventricular arrhythmia (premature ventricular beats and couplets&#xD;
             [&gt;6 premature ventricular contractions per 45 seconds ECG] are considered&#xD;
             significant); and&#xD;
&#xD;
          7. Atrial fibrillation or atrial flutter (event lasting longer than 30 seconds).&#xD;
&#xD;
        Patients who fail the test dose will proceed in the study as follows:&#xD;
&#xD;
          -  If the Investigator identifies a possible reversible cause of the initial test dose&#xD;
             failure (e.g., concomitant medication such as beta-blocker), a re-challenge with a new&#xD;
             test dose of etripamil NS 70 mg will be possible after elimination of the reversible&#xD;
             cause (e.g., withdrawal of concomitant therapy with the appropriate washout period).&#xD;
             Patients may be randomized if they pass the second test dose and the cause of the test&#xD;
             dose failure is eliminated for the duration of the study; or&#xD;
&#xD;
          -  If the Investigator cannot identify a reversible cause of the initial test dose&#xD;
             failure, or if the potential cause cannot be modified (e.g., necessary&#xD;
             antihypertensive drug to control blood pressure), patients will not be randomized and&#xD;
             will complete a Final Study Visit. Patients who fail the test dose will be part of the&#xD;
             Test Dose Only Population, including all patients who received at least 1 test dose of&#xD;
             etripamil NS 70 mg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Plat, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Milestone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas Wight, PhD</last_name>
    <phone>+1-514-336-0444</phone>
    <phone_ext>226</phone_ext>
    <email>dwight@milestonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Raymond</last_name>
      <phone>602-456-2342</phone>
      <email>sraymond@azheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Vijendra Swarup, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbi Philips</last_name>
      <phone>501-227-7596</phone>
      <phone_ext>1263</phone_ext>
      <email>bphillips@acard.org</email>
    </contact>
    <investigator>
      <last_name>Gerald Greer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Robleto</last_name>
      <phone>818-286-3989</phone>
      <email>Melanie@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ramesh Arora, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cardiolog</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diem Phan</last_name>
      <phone>858-349-8919</phone>
    </contact>
    <investigator>
      <last_name>Katherine Ludington, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Alamitos Cardiovascular</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria Ronquillo</last_name>
      <phone>562-430-7533</phone>
      <phone_ext>223</phone_ext>
      <email>riar@losalcardio.com</email>
    </contact>
    <investigator>
      <last_name>Ramandeep Brar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Titan Medical Research - Oceanside</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diem Phan</last_name>
      <phone>858-349-8919</phone>
      <email>Diem.Phan@titanmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Warren Carr, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Soltau</last_name>
      <phone>303-703-2191</phone>
      <email>msoltaue@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Roger Damle, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FWD Clinical Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esthefany Jabbour</last_name>
      <phone>561-484-4466</phone>
    </contact>
    <investigator>
      <last_name>Michael Cammarata, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Ambulatory Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doran Cassidy</last_name>
      <phone>904-202-7218</phone>
      <email>doran.cassidy@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Ruisi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bola Ajose</last_name>
      <phone>404-605-2875</phone>
      <email>bola.ajose@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Bruce Stambler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Burton</last_name>
      <phone>704-410-1116</phone>
      <email>cburton@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Alonzo Jones Sr., Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute- Fayetteville</name>
      <address>
        <city>Fayetteville</city>
        <state>Georgia</state>
        <zip>30214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Stambler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute-Fayetteville</name>
      <address>
        <city>Fayetteville</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Manos</last_name>
      <phone>770-719-5920</phone>
    </contact>
    <investigator>
      <last_name>Bruce Stambler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Arrythmia Consultants&amp;Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>312012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Wolfe</last_name>
      <phone>478-755-1560</phone>
      <email>bwolfe@gacri.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sogade, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri LaMott</last_name>
      <phone>203-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Physicians Group - Cardiology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Miller</last_name>
      <phone>260-266-6628</phone>
      <email>tracy.miller@parkview.com</email>
    </contact>
    <investigator>
      <last_name>David Schleinkofer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy One Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Coulson</last_name>
      <phone>515-633-3843</phone>
      <email>tcoulson@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Denise Sorrentino, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, LLC - Monroe, LA</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Korn</last_name>
      <phone>318-737-1094</phone>
      <email>skorn@ctamerica.net</email>
    </contact>
    <investigator>
      <last_name>Assad Mouhaffel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute - Chesapeake Cardiovascular Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Yashinski</last_name>
      <phone>443-777-2369</phone>
      <email>Cynthia.L.Yashinski@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Glenn Meininger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Mitchell</last_name>
      <phone>517-364-5737</phone>
      <email>sandra.mitchell@sparrow.org</email>
    </contact>
    <investigator>
      <last_name>John Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natella Fridman</last_name>
      <email>jei9008@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>John Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanger Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Bender</last_name>
      <phone>980-442-4900</phone>
    </contact>
    <investigator>
      <last_name>Joseph Thompson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latisha Morgan</last_name>
      <phone>704-264-1400</phone>
      <email>lmorgan@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Kambur, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hatton Institute for Research &amp; Education, Trihealth, Inc. - cardiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Reilly</last_name>
      <phone>513-862-2877</phone>
      <email>susan_reilly2@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Gaurang Gandhi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University (OSU) Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianne Miller</last_name>
      <phone>614-688-8252</phone>
      <email>adrianne.miller3@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph Augostini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rama Research LLC</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Bender</last_name>
      <phone>740-383-7039</phone>
      <email>doka107@aol.com</email>
    </contact>
    <investigator>
      <last_name>Bhola Rama, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart House Research Foundation, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bruner</last_name>
      <phone>937-323-1404</phone>
      <email>hhrf.tbruner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pradeep Gujja, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Schmidt</last_name>
      <phone>419-842-3025</phone>
      <email>shirley.schmidt@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Phelan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Anderson</last_name>
      <phone>605-755-3755</phone>
      <email>danderson14@monument.health</email>
    </contact>
    <investigator>
      <last_name>Saverio Barbera, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Texas Research Associates</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saleem Akbar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Clinic of North Texas</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asaf Usman</last_name>
      <email>namsu34@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Salman Malik, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIM Trials</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waseem Chughtai</last_name>
      <phone>214-578-4983</phone>
      <email>waseem.chughtai@aimtrials.com</email>
    </contact>
    <investigator>
      <last_name>Vijay J. Jayachandran, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harold</last_name>
      <phone>731-798-1037</phone>
      <email>harold@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Lam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital: Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizzie Kiesle</last_name>
      <phone>254-724-1083</phone>
    </contact>
    <investigator>
      <last_name>James Black, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Heart</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Moussi</last_name>
      <phone>832-905-5940</phone>
      <email>emoussi@bayareaheart.com</email>
    </contact>
    <investigator>
      <last_name>Shah Rakesh, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHC Health Services Inc. DBA Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Behunin</last_name>
      <phone>801-507-4760</phone>
      <email>Amanda.behunin@imail.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Anderson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Du Sud- Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Willame</last_name>
      <phone>+32 63231340</phone>
    </contact>
    <investigator>
      <last_name>George Mairesse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Staessen</last_name>
      <phone>32 15 50 62 01</phone>
    </contact>
    <investigator>
      <last_name>Tom Rossenbacker, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles (ULB) - Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Casado</last_name>
      <phone>32 2 555 56 81</phone>
    </contact>
    <investigator>
      <last_name>Ruben Casado, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVC Brugmann University Hospital - Centre Hospitalier Universitaire (CHU)</name>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabil Hayef</last_name>
      <phone>+32 2 477 25 88</phone>
    </contact>
    <investigator>
      <last_name>Emmanuel Catez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen (UZA)</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apotheek Uza</last_name>
      <phone>32 3 821 49 47</phone>
    </contact>
    <investigator>
      <last_name>Hein Heidbuchel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Van Genechten</last_name>
      <phone>32 11 33 70 30</phone>
      <email>Gregory.VanGenechten@Jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Johan Vijgen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital (UZ) Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Goris</last_name>
      <phone>32 16342835</phone>
    </contact>
    <investigator>
      <last_name>Peter Haemers, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Centre Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexa Jonas</last_name>
      <phone>32 4 225 67 31</phone>
    </contact>
    <investigator>
      <last_name>Etienne Hoffer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Godart</last_name>
      <phone>32 65 41 38 21</phone>
      <email>pascal.godart@hap.be</email>
    </contact>
    <investigator>
      <last_name>Pascal Godart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Xhaet</last_name>
      <email>Olivier.xhaet@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Olivier Xhaet, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta - University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McKeage</last_name>
      <phone>403-210-6047</phone>
    </contact>
    <investigator>
      <last_name>Stephen Wilton, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wei</last_name>
      <phone>604-875-5014</phone>
      <email>matthew.wei@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Bennett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials, Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Patterson</last_name>
      <phone>250-595-0400</phone>
      <phone_ext>2</phone_ext>
    </contact>
    <investigator>
      <last_name>Laurence Sterns, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, St Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Muise</last_name>
      <phone>204-235-3501</phone>
    </contact>
    <investigator>
      <last_name>Clarence Khoo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University - QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Schraefel</last_name>
      <phone>902-473-7733</phone>
    </contact>
    <investigator>
      <last_name>Amir Abdel-Wahab, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge Cardiac Care Centre</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Gebeyehu</last_name>
      <phone>519-624-3511</phone>
      <email>gebeyehubeth@cambridgecardiaccare.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Pandey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawson Road Medical Centre</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam DeRose</last_name>
      <phone>226-337-1841</phone>
      <email>aderose@dawsonclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Doug Friars, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>M2R 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Nemtean</last_name>
      <phone>905 895 4521</phone>
      <email>dnemtean@rogers.com</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Parsons</last_name>
      <phone>416-864-5413</phone>
    </contact>
    <investigator>
      <last_name>Victoria Korley, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Robitaille</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3489</phone_ext>
    </contact>
    <investigator>
      <last_name>Blandine Mondesert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyne Gauhtier</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>2068</phone_ext>
    </contact>
    <investigator>
      <last_name>Benoit Coutu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie De Quebec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Chateauvert</last_name>
      <phone>415-656-8711</phone>
      <phone_ext>3023</phone_ext>
    </contact>
    <investigator>
      <last_name>Karine Roy, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Line Morin</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12852</phone_ext>
    </contact>
    <investigator>
      <last_name>Jean-Francois Roux, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lajos Pataki</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Hornyik, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belvarosi Egeszseghaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geza Lupkovics</last_name>
    </contact>
    <investigator>
      <last_name>Geza Lupkovics, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum - Locatie Amersfoort</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816TE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Goor</last_name>
      <phone>31 33 476 82 92</phone>
    </contact>
    <investigator>
      <last_name>Sebastiaan Velthuis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate - Locatie Arnhem</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Halbers</last_name>
      <phone>31 880 056 319</phone>
    </contact>
    <investigator>
      <last_name>Ron Pisters, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen Blaricum</name>
      <address>
        <city>Blaricum</city>
        <zip>1261 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Verduyn</last_name>
      <phone>31 88 753 2135</phone>
      <email>everduyn@tergooi.nl</email>
    </contact>
    <investigator>
      <last_name>Ward Jansen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis - Locatie Breda Molengracht</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Ladak</last_name>
      <phone>+31 76 595 5498</phone>
    </contact>
    <investigator>
      <last_name>Marco Aligns, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pim Langendijk</last_name>
      <phone>31 15 260 3383</phone>
    </contact>
    <investigator>
      <last_name>Gerhard Jan Willem Bech, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurits Arbouw</last_name>
      <phone>31 570 536525</phone>
    </contact>
    <investigator>
      <last_name>Y.S. Tuininga, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ropcke-Zweers Ziekenhuis</name>
      <address>
        <city>Hardenberg</city>
        <zip>7772 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Beijering</last_name>
      <phone>31 52 3276449</phone>
      <email>m.beijering@sxb.nl</email>
    </contact>
    <investigator>
      <last_name>B Van Bemmel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Arnoldus</last_name>
      <phone>31 71 5828001</phone>
    </contact>
    <investigator>
      <last_name>Tjeerd Romer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Luermans</last_name>
    </contact>
    <investigator>
      <last_name>Justin Luermans, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis ziekenhuis - Locatie Roosendaal</name>
      <address>
        <city>Roosendaal</city>
        <zip>4708 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Brans-Boeren</last_name>
      <phone>+31 887068313</phone>
    </contact>
    <investigator>
      <last_name>Reinhart Dorman, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-065</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Balak</last_name>
      <phone>48 728 400 535</phone>
    </contact>
    <investigator>
      <last_name>Wojciech Balak, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne KERmed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Kasprzak</last_name>
      <phone>48 600 181 332</phone>
    </contact>
    <investigator>
      <last_name>Michal Kasprzak, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prywatny Specjalistyczny Gabinet Internistyczny</name>
      <address>
        <city>Libiąż</city>
        <zip>32-590</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Nowak</last_name>
      <phone>48 508 388 200</phone>
    </contact>
    <investigator>
      <last_name>Jacek Nowak, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MEDICOME Sp. z o.o.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Witol Zmuda</last_name>
      <phone>48 505 121 703</phone>
    </contact>
    <investigator>
      <last_name>Witol Zmuda, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Szpital Specjalistyczny w Pulawach</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Gniot</last_name>
      <phone>48 601 815 530</phone>
    </contact>
    <investigator>
      <last_name>Jacek Gniot, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Pro Cordis Sopockie Centrum Badan Kardiologicznych</name>
      <address>
        <city>Sopot</city>
        <zip>81-717</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Miekus</last_name>
      <phone>48 60 1644482</phone>
    </contact>
    <investigator>
      <last_name>Pawel Miekus, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Szpital Specjalistyczny w Pulawach</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar Bebenek</last_name>
    </contact>
    <investigator>
      <last_name>Waldemar Bebenek, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36213</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Iniguez Romo</last_name>
      <phone>34 986 825564</phone>
      <email>andres.iniguez.romo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Andres Iniguez Romo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Guerrero</last_name>
      <phone>34 93 260 72 29</phone>
      <email>sonia.guerrero.moreno@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Anguera Camos, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Rivas Gandara</last_name>
    </contact>
    <investigator>
      <last_name>Nuria Rivas Gandara, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Gomez Salcedo</last_name>
      <phone>912071471</phone>
    </contact>
    <investigator>
      <last_name>Jose Luis Meruno Llorens, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Perez Diez</last_name>
    </contact>
    <investigator>
      <last_name>Diego Perez Diez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martinez Basterra</last_name>
    </contact>
    <investigator>
      <last_name>Javier Martinez Basterra, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Guillot</last_name>
      <phone>+34 648071070</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Ruiz Granell, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal supraventricular tachycardia</keyword>
  <keyword>cardiac monitoring</keyword>
  <keyword>atrioventricular nodal reentrant tachycardia</keyword>
  <keyword>atrioventricular reciprocating tachycardia</keyword>
  <keyword>calcium channel blocker</keyword>
  <keyword>conversion rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etripamil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

